018680.Kq

The company maintains a relatively strong liquidity position, with cash and equivalents amounting to KRW 9,947.5 million, which is sufficient to cover its long-term debt of KRW 17,391.8 million by a margin of 57%. The liquidity FPT (free cash flow to total liabilities) is 8.1%, indicating a moderate ability to service liabilities from operating cash flows. The current ratio of 2.28 suggests the company has a solid short-term liquidity buffer, with current assets more than double its current liabilities.

Profitability metrics show mixed performance. The company reported a net income of KRW 753.6 million, but its operating income was negative at KRW -1,279.4 million, indicating operational challenges. Return on equity (ROE) is 1.84%, and return on assets (ROA) is 1.05%, both below the typical thresholds for strong performance in the pharmaceutical industry. Gross profit of KRW 31,502.98 million represents 60.4% of revenue, which is in line with industry norms, but the negative operating income suggests inefficiencies in cost management or pricing.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases exposure to market-specific risks, particularly in its primary operating region.

Looking ahead, the company is projected to experience a modest revenue decline in the current fiscal year, with a negative operating income expected to persist. The free cash flow of KRW 2,522.06 million provides some flexibility for reinvestment or debt reduction, but capital expenditures of KRW -893.72 million suggest ongoing investment in infrastructure or R&D. The company's diluted earnings per share (EPS) is estimated at KRW 28.00, based on the latest analyst estimates.

The company faces moderate liquidity risk due to its negative net cash position after subtracting total debt. While the debt-to-equity ratio of 0.42 is relatively low, the negative operating income raises concerns about the sustainability of its debt obligations. The risk of dilution is currently assessed as low, with no significant dilution events reported in the latest filings. No recent equity issuance or ATM/shelf registration has been disclosed that would suggest near-term dilution pressure.

No recent material events, such as earnings calls, regulatory filings, or major business announcements, have been disclosed in the available data. The company's financial performance appears to be in a transitional phase, with a focus on managing operational costs and maintaining liquidity.